Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosdagrocorat in Rheumatoid Arthritis
NCT01393639Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2011
- Primary completion
- Jun 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of fosdagrocorat in rheumatoid arthritis (RA) (7 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology Criteria at 8 weeks, Procollagen Type 1 N Terminal Propeptide at 8 weeks and 1 more. Started Sep 2011; status: completed.
02
Drugs
fosdagrocorat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01393639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01393639.